155 related articles for article (PubMed ID: 21344486)
1. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates.
Thiele S; Rauner M; Goettsch C; Rachner TD; Benad P; Fuessel S; Erdmann K; Hamann C; Baretton GB; Wirth MP; Jakob F; Hofbauer LC
J Cell Biochem; 2011 Jun; 112(6):1593-600. PubMed ID: 21344486
[TBL] [Abstract][Full Text] [Related]
2. Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling.
Jin F; Qu X; Fan Q; Wang L; Tang T; Hao Y; Dai K
Mol Med Rep; 2013 Nov; 8(5):1486-92. PubMed ID: 24064566
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
[TBL] [Abstract][Full Text] [Related]
4. WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo.
Thiele S; Göbel A; Rachner TD; Fuessel S; Froehner M; Muders MH; Baretton GB; Bernhardt R; Jakob F; Glüer CC; Bornhäuser M; Rauner M; Hofbauer LC
J Bone Miner Res; 2015 Mar; 30(3):471-80. PubMed ID: 25224731
[TBL] [Abstract][Full Text] [Related]
5. A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer.
Wang Q; Symes AJ; Kane CA; Freeman A; Nariculam J; Munson P; Thrasivoulou C; Masters JR; Ahmed A
PLoS One; 2010 May; 5(5):e10456. PubMed ID: 20454608
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
7. MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3.
Revet I; Huizenga G; Koster J; Volckmann R; van Sluis P; Versteeg R; Geerts D
Cancer Lett; 2010 Mar; 289(2):195-207. PubMed ID: 19815336
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.
Dai J; Hall CL; Escara-Wilke J; Mizokami A; Keller JM; Keller ET
Cancer Res; 2008 Jul; 68(14):5785-94. PubMed ID: 18632632
[TBL] [Abstract][Full Text] [Related]
9. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer.
Zhang H; Yu C; Dai J; Keller JM; Hua A; Sottnik JL; Shelley G; Hall CL; Park SI; Yao Z; Zhang J; McCauley LK; Keller ET
Oncogene; 2014 May; 33(19):2464-77. PubMed ID: 23752183
[TBL] [Abstract][Full Text] [Related]
11. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase.
Yamamoto H; Oue N; Sato A; Hasegawa Y; Yamamoto H; Matsubara A; Yasui W; Kikuchi A
Oncogene; 2010 Apr; 29(14):2036-46. PubMed ID: 20101234
[TBL] [Abstract][Full Text] [Related]
12. Wnt5a suppresses tumor formation and redirects tumor phenotype in MMTV-Wnt1 tumors.
Easter SL; Mitchell EH; Baxley SE; Desmond R; Frost AR; Serra R
PLoS One; 2014; 9(11):e113247. PubMed ID: 25401739
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype.
Milone MR; Pucci B; Bifulco K; Iannelli F; Lombardi R; Ciardiello C; Bruzzese F; Carriero MV; Budillon A
Oncotarget; 2015 Mar; 6(7):5324-41. PubMed ID: 25481874
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.
Chen G; Shukeir N; Potti A; Sircar K; Aprikian A; Goltzman D; Rabbani SA
Cancer; 2004 Sep; 101(6):1345-56. PubMed ID: 15316903
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
16. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer.
Ying J; Li H; Yu J; Ng KM; Poon FF; Wong SC; Chan AT; Sung JJ; Tao Q
Clin Cancer Res; 2008 Jan; 14(1):55-61. PubMed ID: 18172252
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer.
Chen WY; Liu SY; Chang YS; Yin JJ; Yeh HL; Mouhieddine TH; Hadadeh O; Abou-Kheir W; Liu YN
Oncotarget; 2015 Jan; 6(1):441-57. PubMed ID: 25436980
[TBL] [Abstract][Full Text] [Related]
18. p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1.
Hall CL; Zhang H; Baile S; Ljungman M; Kuhstoss S; Keller ET
Cancer Res; 2010 Dec; 70(23):9916-26. PubMed ID: 21098705
[TBL] [Abstract][Full Text] [Related]
19. MiR-26a inhibits prostate cancer progression by repression of Wnt5a.
Zhao S; Ye X; Xiao L; Lian X; Feng Y; Li F; Li L
Tumour Biol; 2014 Oct; 35(10):9725-33. PubMed ID: 24972966
[TBL] [Abstract][Full Text] [Related]
20. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
